• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

寻找表皮生长因子受体的新型抑制剂。

Looking for New Inhibitors for the Epidermal Growth Factor Receptor.

机构信息

REQUIMTE, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Rua do Campo Alegre, 687, 4169-007 Porto, Portugal.

出版信息

Curr Top Med Chem. 2018;18(3):219-232. doi: 10.2174/1568026618666180329123023.

DOI:10.2174/1568026618666180329123023
PMID:29595111
Abstract

Epidermal Growth Factor Receptor (EGFR) is still the main target of the Head and Neck Squamous Cell Cancer (HNSCC) because its overexpression has been detected in more than 90% of this type of cancer. This overexpression is usually linked with more aggressive disease, increased resistance to chemotherapy and radiotherapy, increased metastasis, inhibition of apoptosis, promotion of neoplastic angiogenesis, and, finally, poor prognosis and decreased survival. Due to this reason, the main target in the search of new drugs and inhibitors candidates is to downturn this overexpression. Quantitative Structure-Activity Relationship (QSAR) is one of the most widely used approaches while looking for new and more active inhibitors drugs. In this contest, a lot of authors used this technique, combined with others, to find new drugs or enhance the activity of well-known inhibitors. In this paper, on one hand, we will review the most important QSAR approaches developed in the last fifteen years, spacing from classical 1D approaches until more sophisticated 3D; the first paper is dated 2003 while the last one is from 2017. On the other hand, we will present a completely new QSAR approach aimed at the prediction of new EGFR inhibitors drugs. The model presented here has been developed over a dataset consisting of more than 1000 compounds using various molecular descriptors calculated with the DRAGON 7.0© software.

摘要

表皮生长因子受体(EGFR)仍然是头颈部鳞状细胞癌(HNSCC)的主要靶点,因为超过 90%的这种癌症都检测到其过表达。这种过表达通常与更具侵袭性的疾病、增加对化疗和放疗的耐药性、增加转移、抑制细胞凋亡、促进肿瘤血管生成有关,最终导致预后不良和生存率降低。由于这个原因,在寻找新药物和抑制剂候选物时,主要目标是降低这种过表达。定量构效关系(QSAR)是寻找新的、更有效的抑制剂药物时最广泛使用的方法之一。在这方面,许多作者使用这种技术,结合其他技术,寻找新的药物或增强知名抑制剂的活性。在本文中,一方面,我们将回顾过去十五年开发的最重要的 QSAR 方法,从经典的 1D 方法到更复杂的 3D 方法;第一篇论文发表于 2003 年,最后一篇论文发表于 2017 年。另一方面,我们将介绍一种全新的 QSAR 方法,旨在预测新的 EGFR 抑制剂药物。这里提出的模型是在一个由超过 1000 种化合物组成的数据集上开发的,使用了各种分子描述符,这些描述符是用 DRAGON 7.0©软件计算的。

相似文献

1
Looking for New Inhibitors for the Epidermal Growth Factor Receptor.寻找表皮生长因子受体的新型抑制剂。
Curr Top Med Chem. 2018;18(3):219-232. doi: 10.2174/1568026618666180329123023.
2
Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines.细胞周期蛋白D1表达失调与选择性表皮生长因子受体酪氨酸激酶抑制剂吉非替尼在头颈部鳞状细胞癌细胞系中的疗效降低有关。
Clin Cancer Res. 2004 Nov 15;10(22):7764-74. doi: 10.1158/1078-0432.CCR-04-0012.
3
Epidermal growth factor receptor biology in head and neck cancer.头颈部癌中的表皮生长因子受体生物学
J Clin Oncol. 2006 Jun 10;24(17):2666-72. doi: 10.1200/JCO.2005.04.8306.
4
Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.通过ErbB2和ErbB3的信号传导与头颈部鳞状细胞癌细胞中的耐药性以及表皮生长因子受体(EGFR)扩增相关,且对EGFR抑制剂吉非替尼敏感。
Clin Cancer Res. 2006 Jul 1;12(13):4103-11. doi: 10.1158/1078-0432.CCR-05-2404.
5
Growth factor expression mediates resistance to EGFR inhibitors in head and neck squamous cell carcinomas.生长因子表达介导头颈部鳞状细胞癌对表皮生长因子受体抑制剂的耐药性。
Oral Oncol. 2016 May;56:62-70. doi: 10.1016/j.oraloncology.2016.03.008. Epub 2016 Mar 26.
6
Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells.p27KIP1和p21CIP1/WAF1在表皮生长因子受体酪氨酸激酶抑制剂ZD1839(“易瑞沙”)对头颈部鳞状癌细胞的抗增殖作用中起关键作用。
J Cell Physiol. 2003 Apr;195(1):139-50. doi: 10.1002/jcp.10239.
7
Structural investigations of T854A mutation in EGFR and identification of novel inhibitors using structure activity relationships.表皮生长因子受体(EGFR)中T854A突变的结构研究及利用构效关系鉴定新型抑制剂
BMC Genomics. 2015;16 Suppl 5(Suppl 5):S8. doi: 10.1186/1471-2164-16-S5-S8. Epub 2015 May 26.
8
In vitro study of normoxic epidermal growth factor receptor-induced hypoxia-inducible factor-1-alpha, vascular endothelial growth factor, and BNIP3 expression in head and neck squamous cell carcinoma cell lines: Implications for anti-epidermal growth factor receptor therapy.头颈部鳞状细胞癌细胞系中常氧表皮生长因子受体诱导的缺氧诱导因子-1α、血管内皮生长因子和BNIP3表达的体外研究:抗表皮生长因子受体治疗的意义
Head Neck. 2015 Aug;37(8):1150-62. doi: 10.1002/hed.23733. Epub 2014 Jul 7.
9
IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer.IMC-C225,一种用于治疗头颈癌的抗表皮生长因子受体单克隆抗体。
Semin Oncol. 2002 Oct;29(5 Suppl 14):18-30. doi: 10.1053/sonc.2002.35644.
10
Enhancement of radiosensitivity in head and neck cancer cells by ZD1839 ('IRESSA'), a selective epidermal growth factor receptor tyrosine kinase inhibitor.选择性表皮生长因子受体酪氨酸激酶抑制剂ZD1839(“易瑞沙”)增强头颈部癌细胞的放射敏感性
Am J Clin Oncol. 2003 Oct;26(5):e150-6. doi: 10.1097/01.coc.0000091356.25759.69.

引用本文的文献

1
Bispecific antibodies: unleashing a new era in oncology treatment.双特异性抗体:开启肿瘤治疗的新时代。
Mol Cancer. 2025 Aug 4;24(1):212. doi: 10.1186/s12943-025-02390-y.
2
Drug repurposing to identify potential FDA-approved drugs targeting three main angiogenesis receptors through a deep learning framework.通过深度学习框架进行药物重新利用,以确定针对三种主要血管生成受体的潜在FDA批准药物。
Mol Divers. 2025 May 26. doi: 10.1007/s11030-025-11214-6.
3
Nimotuzumab combined with radiotherapy+/- chemotherapy for definitive treatment of locally advanced squamous cell carcinoma of head and neck: a metanalysis of randomized controlled trials.
尼妥珠单抗联合放疗±化疗用于局部晚期头颈部鳞状细胞癌的根治性治疗:一项随机对照试验的荟萃分析
Front Oncol. 2024 Jun 13;14:1380428. doi: 10.3389/fonc.2024.1380428. eCollection 2024.
4
Kremen2 drives the progression of non-small cell lung cancer by preventing SOCS3-mediated degradation of EGFR.Kremen2 通过阻止 SOCS3 介导的 EGFR 降解来驱动非小细胞肺癌的进展。
J Exp Clin Cancer Res. 2023 Jun 3;42(1):140. doi: 10.1186/s13046-023-02692-3.
5
In Vitro and In Silico Evaluation of Anticancer Activity of New Indole-Based 1,3,4-Oxadiazoles as EGFR and COX-2 Inhibitors.新型吲哚基 1,3,4-恶二唑类化合物作为 EGFR 和 COX-2 抑制剂的体外和计算机模拟抗癌活性评价。
Molecules. 2020 Nov 7;25(21):5190. doi: 10.3390/molecules25215190.
6
Nimotuzumab for Patients With Inoperable Cancer of the Head and Neck.尼妥珠单抗用于治疗不可切除的头颈癌患者。
Front Oncol. 2020 May 27;10:817. doi: 10.3389/fonc.2020.00817. eCollection 2020.
7
PLEK2 promotes gallbladder cancer invasion and metastasis through EGFR/CCL2 pathway.PLEK2 通过 EGFR/CCL2 通路促进胆囊癌侵袭和转移。
J Exp Clin Cancer Res. 2019 Jun 10;38(1):247. doi: 10.1186/s13046-019-1250-8.
8
Optimization of a Deep-Learning Method Based on the Classification of Images Generated by Parameterized Deep Snap a Novel Molecular-Image-Input Technique for Quantitative Structure-Activity Relationship (QSAR) Analysis.基于参数化深度快照生成图像分类的深度学习方法优化:一种用于定量构效关系(QSAR)分析的新型分子图像输入技术
Front Bioeng Biotechnol. 2019 Mar 28;7:65. doi: 10.3389/fbioe.2019.00065. eCollection 2019.